Savara/$SVRA
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Savara
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Ticker
$SVRA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
59
ISIN
US8051111016
Website
Savara Metrics
BasicAdvanced
$442M
-
-$0.49
0.44
-
Price and volume
Market cap
$442M
Beta
0.44
52-week high
$5.11
52-week low
$1.89
Average daily volume
2.2M
Financial strength
Current ratio
14.914
Quick ratio
14.653
Long term debt to equity
19.999
Total debt to equity
20.08
Profitability
EBITDA (TTM)
-108.244
Management effectiveness
Return on assets (TTM)
-38.97%
Return on equity (TTM)
-75.77%
Valuation
Price to book
2.99
Price to tangible book (TTM)
3.22
Price to free cash flow (TTM)
-4.536
Free cash flow yield (TTM)
-22.05%
Free cash flow per share (TTM)
-46.30%
Growth
Earnings per share change (TTM)
32.41%
3-year earnings per share growth (CAGR)
22.53%
What the Analysts think about Savara
Analyst ratings (Buy, Hold, Sell) for Savara stock.
Bulls say / Bears say
Savara's experimental therapy, molgramostim, met the primary endpoint in a late-stage trial for treating autoimmune pulmonary alveolar proteinosis (aPAP), leading to a 31% increase in share price. (reuters.com)
Analysts have set an average 12-month price target of $8.83 for Savara, indicating a potential upside of over 200% from the current stock price. (stockanalysis.com)
Piper Sandler maintained a 'Buy' rating for Savara with a price target of $7.00, reflecting confidence in the company's growth prospects. (markets.businessinsider.com)
Savara's stock reached a 52-week low of $2.60 amid market challenges, reflecting a significant downturn and investor concerns. (investing.com)
The company reported a loss of $38 million for the financial year ending December 31, 2022, highlighting ongoing profitability challenges. (finance.yahoo.com)
Analysts do not anticipate Savara will be profitable this year, raising concerns about its financial sustainability. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
Savara Financial Performance
Revenues and expenses
Savara Earnings Performance
Company profitability
Savara News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
GlobeNewsWire·2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Accesswire·3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Accesswire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Savara stock?
Savara (SVRA) has a market cap of $442M as of July 04, 2025.
What is the P/E ratio for Savara stock?
The price to earnings (P/E) ratio for Savara (SVRA) stock is 0 as of July 04, 2025.
Does Savara stock pay dividends?
No, Savara (SVRA) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Savara dividend payment date?
Savara (SVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Savara?
Savara (SVRA) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.